HAOHAI BIOTEC News

Haohai Biotech (688366) First Coverage Report: Biomaterials Industry Leaders Build a Comprehensive Platform for Medical Devices+Medical and Aesthetic Consumption

民生證券Apr 17 16:41

Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceili

Zhitong FinanceApr 17 16:18

Tianfeng Securities released a research report on April 11 stating that it gave Haohai Biotech (688366.SH) a purchase rating. The main reasons for the rating include: 1) sales of hyaluronic acid products are growing rapidly, and the company's revenue grow

Zhitong FinanceApr 11 08:10

Haohai Biotech (688366): High-end hyaluronic acid is growing rapidly, and development of ophthalmic products is progressing in an orderly manner

天風證券Apr 10 18:56

Haohai Biotech (688366) Annual Report Review Report: The total volume of hyaluronic acid products is growing steadily in the ophthalmology sector

國盛證券Mar 12 18:27

Haohai Biotechnology (06826.HK): “Sea Charm” continues to be released, and we expect new products to continue the high growth rate of medicine and beauty

東北證券Mar 11 19:11

Haohai Biotech (688366): Hyaluronic acid achieved rapid growth, ophthalmology maintained a rapid growth trend

東吳證券Mar 11 18:16

Haohai Biotech (688366): The 23-year performance is in line with expectations, hyaluronic acid continues to increase, and the new product is still stable, pending approval of the new product

德邦證券Mar 11 07:31

Haohai Biotech (688366): Rapid profit side growth, outstanding performance of medical and aesthetic hyaluronic acid

廣發證券Mar 11 00:00

Haohai Biotech (688366) 23rd Annual Report Review: Hyaluronic Acid Revenue Exceeds 600 Million Yuan, Expecting Organic Crosslinked Hyaluronic Acid Approval to Continue Improving Pipeline Layout

信達證券Mar 10 00:00

Haohai Biotech (688366): The business situation has remained steady and the profit side has grown rapidly in 23 years

廣發證券Feb 26 09:36

Haohai Biotechnology (06826.HK): Net profit is in line with forecast hyaluronic acid-driven performance growth

東北證券Feb 26 00:00

Haohai Biotech (688366): Hyaluronic acid continues to unleash growth potential, stock buybacks highlight confidence in long-term development

國盛證券Feb 25 13:46

Haohai Biotech (688366): Crystal mining reduces prices or affects procurement intentions, focusing on the approval/release progress of new medical and aesthetic products

信達證券Jan 30 19:06

Haohai Biotech (688366): Performance forecast is higher than the previous year, and the operation is steady and improving

財通證券Jan 29 00:00

Haohai Biotechnology (06826.HK): Net profit continues to grow at a high growth rate, hyaluronic acid continues to grow

東北證券Jan 29 00:00

Haohai Biotech (688366): Hyaluronic acid continues to grow at a high rate, driving continuous improvement in profitability

國盛證券Nov 4, 2023 00:00

Haohai Biotech (688366): Profitability of rapid hyaluronic acid release continues to improve

興業證券Nov 3, 2023 00:00

Haohai Biotech (688366): Hyaluronic acid sales performance is good, performance remains high

華福證券Oct 27, 2023 00:00

Haohai Biotech (688366): Profitability continues to increase in 23Q3, hyaluronic acid release and rich medical and aesthetic matrices

德邦證券Oct 26, 2023 18:52